natgillin/translations-raw huggingface dataset:
vHVT301, comprising a wild-type NDV-F gene of the genotype VIId, under the control of an SV40 promoter and an SV40 polyA signal, inserted into the IG2 locus of the HVT genome; 
NDV-F-gen koji ima polinukleotidnu sekvencu prikazanu u SEQ ID BR:1, koji je operativno povezan s SV40 promotorom i SV40 poliA-signalom, i umetnut je u IG1 lokus od HVT genoma; ili
The hinge according to claim 4, characterised in that it comprises second means (18) for adjusting the mutual positions of said two hinge bodies 11 and 12 in a direction substantially orthogonal to the plane of the mobile frame to which the hinge is attached, said second means (18) being independent of said crosswise adjustment means (17). 
Šarka u skladu s patentnim zahtjevom 3, naznačena time, da ima drugo sredstvo (18) za podešavanje uzajamnog položaja dvaju navedenih tijela šarke 11 i 12 u smjeru koji je u biti ortogonalan prema ravnini mobilnog okvira na koji je šarka pričvršćena, pri čemu je drugo sredstvo (18) neovisno od navedenog sredstva za poprečno podešavanje (17).
When the vehicle begins harvesting the forage, the operator would turn on the spraying function of system 10 via switch 115. 
Kada vozilo počne žnjeti krupnu stočnu hranu, operator će uključiti funkciju raspršivanja sustava prekidačem 115.
The concentration of said water in said fluid may according to another aspect of the present invention be up to 99.5% by weight, such as up to 98% by weight, and preferably up to 95% by weight, such as up to 90% by weight, and even more preferably up to 85% by weight, such as up to 80% by weight. 
Metoda u skladu s bilo kojim od patentnih zahtjeva 55-56, pri čemu je koncentracija navedene vode u navedenoj tekućini do 99,5 % prema težini, kao što je do 98 % prema težini, a poželjno do 95 % prema težini, kao što je do 90 % prema težini, a još poželjnije do 85 % prema težini, kao što je do 80 % prema težini.
A method for producing a device according to one or more of claims 21 to 23, wherein said engraving of indicia is performed by a tool selected from the group comprising mechanical ablation tools, gaseous-jet ablation tools, liquid-jet ablation tools, and laser ablation tools. 
Postupak za proizvodnju uređaja sukladno jednom od patentnih zahtjeva 19 do 20, naznačen time, da se navedeno graviranje oznake vrši alatom odabranim iz skupine koju čine mehanički alati za graviranje, alati za graviranje plinskim mlazom, alati za graviranje mlazom tekućine 1 laserski alati za graviranje.
wherein R is alkyl with C1-6 straight or branched chain or C1-2 fully halogenated alkyl, Z is —O—R or —X, wherein R is as described above, X is halogen, and reacting the compound of general formula (IV) obtained wherein R is as described above, 
R-0-CO-Z (VI) pri čemu je R alkil sa C;.g ravnim ili razgranatim lancem ili Ci.2 potpuno halogenizirani alkil, Z je -O-R ili-X, pri čemu je R kako je opisano ranije, X je halogen, i reakcijom smjese opće formule (TV) dobivene
The 19-nor-D-homo steroid derivatives of this invention have the natural configurations 8B, 9a, 10B, 13Band 14a. 
19-Nor-D-homosteroidni derivati prema ovom izumu imaju prirodne konfiguracije 8B, 94, 10B, 13B i 14a.
The method of claim 1, wherein the PPCA polypeptide comprises SEQ ID NO: 4. 
Sastav za uporabu prema zahtjevu 1, naznačen time, da sastav obuhvaća PPCA koji ima aminokiselinsku sekvencu od SEQ ID NO: 4.
Use of high molecular weight polyethylene oxide that has, based on rheological measurements, a molecular weight of at least 1,000,000, as matrix forming material in the manufacture of a solid extended release oral dosage form comprising an active agent selected from opioids for imparting to the solid extended release oral dosage form resistance to alcohol extraction. 
barem jedan aktivni agens odabran od opioidnih analgetika gdje je opioidni analgetik oksikodon hidroklorid i oblik davanja sadrži od 5 mg do 500 mg oksikodon hidroklorida; i gdje sastav sadrži barem oko 80 % (težine) polietilen oksida koji ima, na osnovu reoloških mjerenja, prosječnu molekularnu težinu od barem 1.000.000.
A compound according to Formula (Ia): 
Spoj prema Formuli Ia:
The compound of claim 1, wherein R2 and R3 combine with the nitrogen to which they are attached to form optionally substituted homopiperazinyl. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što se R* i R* kombiniraju s ugljikom na kojeg su vezani kako bi tvorili izborno supstituirani homopiperidinil.
a C1-10 alkylsulfonyloxy group which can be substituted, a C3-7 cycloalkyl - C2-6 alkynyl group which can be substituted, 
karbamoil-skupina koja može biti supstituirana; C1-10 alkilsulfoniloksi-skupina koja može biti supstituirana; C3-7 cikloalkil-C2-6 alkinil-skupina koja može biti supstituirana;
The compound of claim 5, wherein R1 is pyridyl substituted with one or more substituents independently selected from the group consisting of substituted or unsubstituted C1-8 alkyl, substituted or unsubstituted heterocyclyl, halogen, aminocarbonyl, cyano, hydroxyalkyl, -OR, and -NR2, wherein each R is independently H, or a substituted or unsubstituted C1-4 alkyl. 
Spoj u skladu s patentnim zahtjevom 1 ili 2, naznačen time, da R1 je piridil supstituiran s hidroksialkilom; ili gdje je piridil supstituiran sa supstituiranim ili nesupstituiranim triazolilom i supstituiranim ili nesupstituiranim C1-8 alkilom. Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je spoj:
The method of any of paragraphs 1 to 7, wherein the patient has anemia associated with a kidney disorder. 
Polipeptid za uporabu prema bilo kojem od prethodnih zahtjeva, pri čemu pacijent ima anemiju povezanu s poremećajem bubrega, povezanu s kemoterapijskim tretmanom, ili koja nastupa kao posljedica gubitka krvi.
adding an active agent and mixing; 
(b) dodavanje aktivnog sredstva i mješanje;
SUMMARY In the first and second objects of the invention, a technical result is achieved that lies in increasing the efficiency of production of high-viscosity oils during the development of wells by conventional methods used in the oil industry owing to a rise in the permeability of a reservoir and a reduction in the viscosity of oil and in increasing environmental safety owing to the absence of chemically active reagents (acids) and steam generators. 
HR P20080384 T3 Sažetak U prvom i drugom ostvarenju izuma postiže se tehnički rezultat koji zapravo leži u povećanju učinkovitosti proizvodnje nafte visoke viskoznosti za vrijeme razvoja izvora pomoću uobičajenih metoda koje se koriste u naftnoj industriji, a uslijed povećanja propusnosti spremnika, smanjenja viskoznosti nafte i povećanja sigurnosti okoliša zbog odsutnosti kemijskih aktivnih tvari (kiselina) i generatora pare.
providing irbesartan having a maximum particle diameter of not more than 2000 µm, (ii') mixing the irbesartan and one or more excipient(s) to give compression mixture, and 
pribavljanje irbesartan hidroklorida čiji najveći promjer čestice nije veći od 2000 um, (ii') miješanje irbesartan hidroklorida i jedne ili više pomoćnih tvari da bi se dobila smjesa za komprimiranje, te
The polymer according any preceding claim or suitable combination of preceding claims, characterized in that compounds of claim 1 i) (c) are a mixture of compounds (I) in the form of oligomers up to 10 mols per molecule, being the sum of the quantity of monomers, dimers, trimers and tetramers at least 75% in weight-% of the total substituted acetylene carbamide mixture as defined in claim 3 in weight-%. 
Mikrokapsule prema patentnom zahtjevu 1, naznačene time, što su spojevi iz zahtjeva 1 (c) mješavina spojeva (I) u formi oligomera sa do 10 molova po molekuli, pri čemu ukupna količina monomera, dimera, trimera i tetramera iznosi najmanje 75 težinskih-% od ukupne težine spojeva (I).
the Hofmann rearrangement of 1,1-cyclohexanediacetic acid monoamide; the precipitation of gabapentin by acidification of the reaction mixture obtained by said rearrangement to a pH comprised between 4 and 6.3 with an organic or inorganic acid. 
Hofmamovu preraspodjelu monoamida 1,1-cikloheksandioctene kiseline; b. taloženje gabapentina zakiseljavanjem reakcijske smjese, koja je dobivena navedenom preraspodjelom, do pH između 4 i 6.3 pomoću organske ili anorganske kiseline.
VBP15 or VBP6 for use according to Claim 1, wherein said muscular dystrophy is Duchenne muscular dystrophy. 
VBPI5 ili VBP6 za uporabu u skladu s patentnim zahtjevom 1, pri čemu je navedena mišićna distrofija Duchenne mišićna distrofija.
wherein the main catalyst is a water-insoluble acid-resistant alloy; the cocatalyst is a soluble tungstic acid salt and/or an insoluble tungsten compound. 
kokatalizator je topiva sol volframske kiseline i / ili netopivi volframov spoj; diol je etilen glikol; i reakcijski sustav pH je 1 - 7.
A host cell, comprising a nucleic acid or an expression vector according to claim 6, which preferably is an antigen presenting cell, such as, for example, a dendritic cell. 
Stanica domaćin, sastoji se od nukleinske kiseline ili ekspresijskog vektora u skladu s patentnim zahtjevom 5, koja je stanica koja prezentira antigen.
The compound of claim 25, wherein the -(C1-C6) alkyl group is a tert -butyl group or an iso-propyl group. 
. Spoj prema zahtjevu 25, naznačen time da -(Cy-Cg) alkilna skupina je tert-butil skupina ili iso-propil skupina.
Production of the modified Fab fragment in an appropriate system; and 
(b) proizvodnju izmijenjenog Fab fragmenta u odgovarajućem sustavu; i
A therapeutically effective amount of an alpha adrenergic receptor agonist or a pharmaceutically acceptable salt thereof for use in treating at least one of vascular extravasation into the skin and cutaneous manifestations of intrinsic or extrinsic aging of the skin, skin wrinkling, sallow-yellow skin discoloration, dark circles under the eyes, bruising, bruising caused by laser administration, and hyperpigmentation. 
Terapeutski učinkovita količina agonista alfa adrenergijskog receptora ili njegove farmaceutski prihvatljive soli za uporabu u liječenju purpure kod subjekta, naznačena time što je purpura odabrana od solarne purpure, aktinske purpure, senilne purpure, Batemanove purpure, laserski inducirane purpure, purpure uzrokovane fizičkom traumom, purpure uzrokovane fizičkom traumom kože, kožne vaskulature, i/ili okolnih tkiva, purpure uzrokovane medicinskim postupkom, purpure uzrokovane kirurškim zahvatom i njihovim kombinacijama.
A pharmaceutical composition made by mixing a compound of Claim 1 and a pharmaceutically acceptable carrier. 
Farmaceutski sastav napravljen miješanjem spoja iz zahtjeva 1 i farmaceutski prihvatljivog nosača.
PCT/GB2005/000464 demonstrates receptor binding profile broadly similar to the receptor binding profiles of atypical antipsychotic agents. 
PCT/GB2005/000464 pokazuje profil vezivanja receptora uvelike sličan profilima vezivanja receptora atipičnih antipsihotičnih sredstava.
Advantageously both groups of microparticles are microgranules. One group of microparticules is advantageously obtained by mixing, in a solvent-free process, said PLGA with said water insoluble peptide salt. 
Farmaceutski pripravak prema zahtjevu 1 ili 2, gdje se barem jedna od tih skupina mikročestica dobiva miješanjem PLGA a peptidnom soli netopljivom u vodi, u postupku bez otapala.
reacting the second 1,1,1,3-tetrachloropropane solution from step (iii) with chlorine in the presence of ferric chloride under conditions effective to produce 1,1,1,2,3-pentachloropropane; adding the product from step (v) to reactive distillation process equipment comprising a reaction zone, a separation zone, and a condensing zone, and dehydrochlorinating the crude 1,1,1,2,3-pentachloropropane to form hydrogen chloride and 1,1,2,3-tetrachloropropene, and removing hydrogen chloride and 1,1,2,3-tetrachloropropene from the reaction zone during the course of the dehydrochlorinating by distillation, and 
(1ii) reakciju gornjeg protoka s klorom u prisutnosti željezovg(Ill) klorida radi dobivanja sirovog 1,1,1,2,3- pentakloropropana; HR P20140465 T1 (iv) dodavanje sirovog 1,1,1,2,3-pentakloropropana iz koraka (iii) u reakcijsku zonu, koja je dio opreme za postupak reaktivne destilacije koja obuhvaća reakcijsku zonu, zonu odvajanja i zonu kondenzacije, te dehidrokloriranje sirovog 1,1,1,2,3-pentakloropropana radi nastanka klorovodika i 1,1,2,3-tetrakloropropena, i uklanjanje klorovodika i 1,1,2,3-tetrakloropropena destilacijom iz reakcijske zone tijekom dehidrokloriranja, i
The use according to any one of claims 1-8, wherein said composition further comprises at least one chelating agent selected from ethylenediaminetetraacetic acid (EDTA) and ethylene glycol tetraacetic acid (EGTA). 
Upotreba u skladu s bilo kojim od patentnih zahtjeva 1-14, naznačena time što navedeni pripravak dodatno sadrži najmanje jedno kelirajuće sredstvo, koje se bira između etilendiamintetraoctene kiseline (EDTA) i etilen-glikol- tetraoctene kiseline (EGTA).
a cleavable scFc (cscFc) linker interposed between the two Fc moieties, wherein the cscFc linker is linked to at least one enzymatic cleavage site which results in cleavage of the cscFc linker. 
scFc (cscFc) poveznicu koja se može cijepati umetnutu između dva Fc dijela, pri čemu je cscFc poveznica okružena s mjestom enzimatskog cijepanja i uzvodno i nizvodno od cscFc poveznice, što rezultira cijepanjem cscFc poveznice.
This blend was added to the fluidization pan and the drug solution was adsorbed on it by using fluid bed process (top spray process). 
Ova mješavina je dodana u fluidizacijsku posudu te je otopina lijeka adsorbirana na nju rabeći postupak fluidne podloge (fop spray postupak).
The device 1200 may include an interface to a user localization system for receiving the user density map. 
Naprava (1200) u skladu s patentnim zahtjevom 13, naznačena time što sadrži: međusklop prema sustavu za lokalizaciju korisnika za prijem karte gustoće korisnika.
p ranges from 1-8, and preferably from 2-5. 
p iznosi u rasponu od 1 do 8, a poželjno od 2 do 5.
A human monoclonal antibody that is capable of specifically binding to a human CD40 antigen expressed on the surface of a human CD40-expressing cell, said monoclonal antibody being free of significant agonist activity, wherein said monoclonal antibody exhibits increased anti-tumor activity relative to an equivalent amount of the monoclonal chimeric anti-CD20 monoclonal antibody IDEC-C2B8, wherein said anti-tumor activity is assayed in a staged nude mouse xenograft tumor model using the Daudi human B cell lymphoma cell line, wherein said antibody is optionally selected from the group consisting of: 
Humano monoklonalno antitijelo koje se može specifično vezati za humani CD40 antigen koji je eksprimirao na površini humane CD40-ekspresijske stanice, navedeno monoklonalno antitijelo je slobodno od značajnog agonističkog djelovanja, gdje, kada se navedeno monoklonalno antitijelo veže za CD40 antigen eksprimirani na površini navedene stanice, rast ili diferencijacija navedene stanice je inhibirana, gdje je navedeno antitijelo odabrano od skupine koja se sastoji od:
The method of claim 1, wherein the concentration of the aqueous dispersion is 0.5 to 3% when applied. 
Korištenje sukladno zahtjevu 1, naznačeno time da je prilikom primjene poželjna koncentracija vodene disperzije 0,5 do 3%.
a contiguous sequence of the human λ light chain locus that spans from Vλ3-29 to Vλ3-1; or 
graničnu sekvencu lokusa humanog lakog lanca λ koja se proteže od hVλ3- 27 do hVλ3-1; ili
Compounds of the present invention may also be beneficial in preventing, treating or ameliorating a variety of diseases, such as dermal diseases or conditions, such as proliferative and inflammatory skin disorders and in particular psoriasis, epidermal inflammation, alopecia, skin atrophy, steroid induced skin atrophy, skin ageing, photo skin ageing, acne, dermatitis, atopic dermatitis, seborrheic dermatitis, contact dermatitis, urticaria, pruritis, and eczema. 
Spoj koji je 2-(3,5-Dikloro-1-oksido-piridin-4-il)-1-(9-difluorometoksi-spiro[2H-1,5-benzodioksepin-3(4H),3'- oksetan]-6-il)etanon, ili farmaceutski prihvatljiv hidrat ili solvat istoga, za uporabu u liječenju proliferativnih i upalnih kožnih poremećaja poput psorijaze, epidermalne upale, akni, dermatitisa, atopijskog dermatitisa, seboreičnog dermatitisa, kontaktnog dermatitisa, urtikarije, pruritisa i ekcema.
A composition comprising a binding polypeptide of any one of the preceding claims and a pharmaceutically acceptable carrier or excipient. 
Pripravak naznačen time da sadrži protutijelo iz bilo kojeg od prethodnih patentnih zahtjeva, te farmaceutski prihvatljiv nosač ili pomoćno sredstvo.
The compound according to item 2 wherein A is selected from the group consisting of 
Spoj u skladu s patentnim zahtjevom 2, naznačen time, da je A odabran iz skupine koja se sastoji od
treating the compound of formula (7) or a pharmaceutically acceptable salt thereof, as a single stereoisomer or enantiomer or a mixture thereof, with a base under suitable conditions to form a compound of formula (8): or a pharmaceutically acceptable salt thereof, as a single stereoisomer or enantiomer or a mixture thereof; 
OH ili njegovu farmaceutski prihvatljivu sol, u obliku pojedinačnog stereoizomera ili enantiomera ili njihove smjese; obradi spoja formule (7), ili njegove farmaceutski prihvatljive soli, u obliku pojedinačnog stereoizomera ili enantiomera ili njihove smjese, bazom u uvjetima pogodnim za dobivanje spoja formule (8):
loading a cation exchange column with the eluent from the anion exchange column of step (c) under conditions permitting capture of the non-complexed botulinum toxin A by the cation exchange column; and 
stavljanja u stupac za kationsku izmjenu eluensa iz stupca za anionsku izmjenu iz koraka (c) u uvjetima koji omogućavaju skupljanje nekompleksiranog botulinskog toksina A u stupcu za kationsku izmjenu; i
This embodiment is similar to the one described above with reference to FIG. 7 and the apparatus comprises a volume filling device in the form of an inflatable device 10 which is invaginated in the wall 12 a of the patient's stomach 12 . However, in this case the invagination has been performed in the fundus, i.e., the upper portion of the stomach, where the number of receptors in the stomach wall is large, and the inflatable device functions as a stretching device for part of the stomach fundus wall. 
Uređaj u skladu s patentnim zahtjevom 5, naznačen time što je tijelo proširljivo tijelo, prilagođeno da bude invaginirano dijelom stijenke pacijentovog želuca, te što uređaj za rukovanje ima spremnik fluida (16; 46; 52; 90; 452), koji je u fluidnoj komunikaciji s komorom proširljivog tijela, gdje se uređajem za rukovanje može neinvazivno rukovati radi distribuiranja fluida iz spremnika fluida u komoru proširljivog tijela kako bi se proširilo tijelo, tako da se dio stijenke želuca rastegne kada je proširljivo tijelo invaginirano.
The method of claim 1, wherein the formulation is selected from the group consisting of: 
Kruta oralna farmaceutska formulacija prema zahtjevu 1, naznačena time što je formulacija kapsula odabrana iz skupine koja sadrži:
The shell 14 has an inward curl 44, see Figure 3, formed on its lower edge, and this inward curl engages the outer surface 4 of the cup wall 22 above the lower end of the cup 12 at a distance corresponding approximately to the height of the cup bottom 24. 
Ljuska 14 ima zavijutak 44 prema unutarnjoj strani, vidi sliku 3, koji zavijutak je načinjen na donjem rubu i ovaj zavijutak prema unutarnjoj strani zahvaća vanjsku površinu 4 stijenke tijela čaše 29 iznad donjeg kraja čaše 12 na razmaku koji odgovara približno visini od dna 24 čaše.
The method of claim 1, wherein the microparticles have an average diameter of 0.01 um-100 um. The method of claim 20, wherein the microparticles have an average diameter of 0.01 um-50 um. 
Smjesa iz patentnog zahtjeva 1 ili 2, naznačena time, da mikročestice imaju prosječni promjer od 0,01 um - 100 jim, poželjno je od 0,01 um - 50 um.
Use of a tumour associated peptide according to Claim 1 or 2 or a nucleic acid according to Claim 4 or an expression vector according to Claim 5 for the manufacture of a medicament for inducing an immune response, in particular a cellular immune response, more particularly a T-cell mediated immune response against cells of solid tumours which cells express a human class II MHC molecule on their surface and present a polypeptide comprising an amino acid sequence as given in Claim 1 or 2. 
Upotreba tumoru pridruženih peptida prema bilo kojem od Zahtjeva 1 do 3 ili nukleinske kiseline prema Zahtjevu 4 staničnog imunološkog odgovora, specifičnije za imunološki odgovor posredovan T limfocitima protiv stanica solidnih tumora koje eksprimiraju humane MHC molekule razreda II na svojoj površini te prikazuju polipeptid koji se sastoji od slijeda aminokiselina navedenog u bilo kojem od Zahljeva 1 ili 2.
Compounds according to the present invention may be monoacylated at C-10, such as when R5 and R6 are hydroxyl and R4 is R7COO, where R7COO has a formula selected from the following structures: 
Opisani spojevi mogu biti monoacilirani na C-10, kao npr. kada su Rs i Rg hidroksil, a Ra je R;COO, gdje R;COO ima formulu 5. kojaje odabrana iz sljedećih struktura: um HOO Po
Thus, in a preferred embodiment of the present invention the pharmaceutical composition containing at least one antigen presenting cell is pulsed or loaded with the peptide, for instance by the method of example 4. 
Farmaceutski sastav prema zahtjevu 7 ili 8, gdje je najmanje jedna stanica koja predstavlja antigen a) -pulsirana ili napunjena peptidom, ili b) sadrži ekspresijski konstrukt u koji je ukodiran peptid.
The glycosylated human SAP polypeptide of claim 14, wherein the one or more modified amino acid residues comprise a PEGylated amino acid, a prenylated amino acid, an acetylated amino acid, a biotinylated amino acid, and/or an amino acid conjugated to an organic derivatizing agent. 
Glikozilirani humani SAP polipeptid u skladu s patentnim zahtjevom 14, naznačen time, da jedan ili više modificiranih aminokiselinskih ostataka obuhvaća PEGilirane amilno kiseline, preniliranu amino kiselinu, acetiliranu aminokiselinu, biotiniliranu aminokiselinu, i/ili amino kiselinu konjugiranu na organsko derivatizirajuće sredstvo.
The formulation of claim 10, wherein the tonicity modifier is present in the formulation at a concentration wherein the formulation is approximately isotonic. 
Formulacija iz patentnog zahtjeva 10, pri čemu je modifikator tonusa prisutan u formulaciji u koncentraciji dovoljnoj za približno izotoničnu formulaciju.
a termination signal. A recombinant vector according to claim 9, wherein said recombinant vector is capable of being replicated, transcribed, translated and expressed in a unicellular organism. 
Rekombinantni vektor prema patentnom zahtjevu 7, naznačen time da je navedeni rekombinantni vektor u stanju Teplicirati se, transkribirati, prevesti i eksprimirati se u jednostaničnom organizmu.
The peptide according to claim 1 or claim 2, or the peptidomimetic according to claim 3, or the conjugate according to any one of claims 4-7 or the pharmaceutical composition of any one of claims 8-10, for use in a method for treatment of ischemia in the human or animal body. 
Peptid u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 2 ili peptidomimetik u skladu s patentnim zahtjevom 3, ili konjugat u skladu s bilo kojim od patentnih zahtjeva 4-7 ili farmaceutski sastav iz bilo kojeg od patentnih zahtjeva 8-10, za uporabu u metodi za liječenje ishemije u ljudskom ili životinjskom tijelu.